-+ 0.00%
-+ 0.00%
-+ 0.00%

Cellectar Biosciences Q3 EPS $(1.41) Beats $(2.53) Estimate

Benzinga·11/13/2025 12:03:04
Listen to the news
Cellectar Biosciences (NASDAQ:CLRB) reported quarterly losses of $(1.41) per share which beat the analyst consensus estimate of $(2.53) by 44.2 percent. This is a 88.25 percent increase over losses of $(12.00) per share from the same period last year.